lead, ABCD audits of new diabetes therapies and devices
Aid to the MRCP Short Cases
An Aid to the MRCP PACES
Co-ordinator & Clinical Lead, Nationwide Audits of New Diabetes Therapies
Bob Ryder trained in
South Wales and Sheffield. He has worked as a Consultant
Physician/Diabetologist/Endocrinologist, City Hospital, Birmingham since 1991.
Over the years special interests have included diabetic retinopathy screening;
diabetic hypoglycaemia unawareness; diabetic autonomic neuropathy; diabetic
impotence; clinical use of IT; treating to target; relative risks and benefits
of pioglitazone He leads the ABCD nationwide audits of new therapies and
devices – current audits include SGLT2i, FreeStyle Libre, semaglutide, COVID 19
and diabetes, testosterone, closed-loop systems, oral semaglutide and Omnipod.
He is chief investigator of two ABCD Endobarrier studies. Beyond diabetes he is
best known as principal author of best-selling "An Aid to the MRCP Short
Cases", the 4th-edition of which is the three volume “An Aid to the MRCP